Colorectal Cancer Treatments: The Role of Stage, Biomarkers, and Immunotherapy

Colorectal cancer treatment depends on stage, location, and tumor biology. This guide explains the decision points that drive modern care—especially the biomarker split that predicts immunotherapy benefit.

Important: This is educational information, not medical advice. Your plan depends on your exact diagnosis, stage, biomarkers, overall health, and preferences.

60-second orientation

  • Colorectal cancer care is driven by stage (localized vs spread) and biomarkers.
  • A key biomarker concept is mismatch repair status:
    • Mismatch repair deficient / MSI-high (dMMR / MSI-H) tumors often respond well to immunotherapy.
    • Microsatellite stable (MSS) tumors usually do not respond as well to immunotherapy by default.
  • Treatment often involves combinations of surgery, chemotherapy, and in some settings radiation and/or targeted/immunotherapies.

Key terms (defined once)

  • CRC (colorectal cancer): includes colon and rectal cancers.
  • MSI-H (microsatellite instability–high): a feature linked to DNA repair problems.
  • dMMR (deficient mismatch repair): another way to describe the same DNA repair problem.
  • MSS (microsatellite stable): tumors without MSI-H/dMMR; this is most cases.
  • Metastatic: cancer has spread to distant organs (commonly liver/lung).
  • Immunotherapy (checkpoint inhibitors): medicines that help immune cells attack cancer; particularly important for MSI-H/dMMR.

Step 1: location matters (colon vs rectum)

Rectal cancer often has a stronger role for radiation and carefully timed therapy because of anatomy and local control needs. Colon cancer is more surgery + systemic therapy driven.

Ask your team: “Is this treated like colon or rectal cancer, and what does that change?”

Step 2: stage (simplified)

  • Early stage (localized): surgery is often the main curative treatment; additional therapy may be used based on recurrence risk.
  • Locally advanced: may require combinations (surgery plus chemotherapy; rectal cancer often includes radiation strategies).
  • Metastatic: systemic therapy is the backbone; surgery may still play a role in selected cases (for example, limited liver metastases).

Step 3: the biomarker split that changes immunotherapy

MSI-H / dMMR

These tumors can be highly responsive to immunotherapy. For some patients, immunotherapy becomes a major part of treatment planning.

MSS

Most colorectal cancers are MSS. Immunotherapy is not routinely effective for most MSS tumors on its own, which is why much research focuses on combination strategies to “prime” immune response.

Ask your team:

  • “What is my MSI or mismatch repair status?”
  • “How does that affect immunotherapy options?”

What treatment typically looks like today (high-level)

A) Localized colon cancer

Common pattern:

  • surgery first (curative intent)
  • chemotherapy afterward for selected higher-risk cases, depending on stage and pathology risk features

B) Rectal cancer (often more complex sequencing)

Rectal cancer can involve:

  • combinations of chemotherapy and radiation
  • surgery depending on response and strategy
  • careful sequencing decisions tailored to stage and local anatomy

C) Metastatic colorectal cancer

Systemic therapy usually includes chemotherapy backbones, sometimes combined with targeted therapies depending on tumor biology (certain mutations or marker profiles can change what’s used).

For MSI-H/dMMR metastatic disease, immunotherapy may become a central option.

What’s changing now (the themes)

  • Better personalization using biomarkers (especially MSI/MMR).
  • More targeted options for certain molecular subsets.
  • Research focus on MSS: combinations designed to make immunotherapy work better for the majority group.
  • Blood-based monitoring is an active area (using circulating tumor DNA in some contexts), especially around recurrence risk after surgery.

Questions to ask your care team (high value)

  1. Is this colon or rectal cancer, and how does that change treatment?
  2. What stage is it, and what is the goal right now?
  3. What is my MSI/MMR status (MSI-H/dMMR vs MSS)?
  4. Were other biomarkers tested that affect targeted therapy options?
  5. If surgery is planned, do I need therapy before or after surgery?
  6. How will we track whether treatment is working?
  7. If the cancer returns or progresses, what are the next options?

Keep your care organized in VisitVizor

Create a free account to store scans, labs, and visit notes in one secure place.

Create free accountSign in

Educational content stays free — no paywall required.

Deep dive: practical “if/then” map

If localized disease and surgery is possible:

  • surgery is often central
  • additional therapy depends on recurrence risk features

If rectal cancer with higher local risk:

  • treatment may involve a carefully timed sequence of chemo and radiation to improve local control

If metastatic disease:

  • systemic therapy is the backbone
  • biomarker results influence whether immunotherapy or targeted approaches are relevant

If MSI-H/dMMR:

  • immunotherapy may be a major option
  • ask how it compares to chemo-based approaches in your situation

If MSS:

  • chemo-based approaches remain central
  • ask about trials if interested in emerging combination strategies

Understanding “response” and “reassessment”

Many metastatic plans are built around reassessment points:

  • a scan after a planned number of cycles
  • a decision about continuing, switching, or adding therapy
  • a plan for side effect management

Ask: “What are our decision points, and what would make us change course?”

Practical: what documents to keep

  • pathology and staging reports
  • biomarker results (especially MSI/MMR)
  • surgery report (if applicable)
  • treatment summary and imaging reports

Sources and review

This guide summarizes commonly used concepts in colorectal cancer decision-making (stage + MSI/MMR-driven immunotherapy relevance).

Last reviewed: 2026-02-01